Efficacy of broadly neutralizing monoclonal antibody PG16 in HIV-infected humanized mice  by Stoddart, Cheryl A. et al.
Efﬁcacy of broadly neutralizing monoclonal antibody PG16
in HIV-infected humanized mice
Cheryl A. Stoddart a,n, Soﬁya A. Galkina a, Pheroze Joshi a, Galina Kosikova a, Brian R. Long a,
Ekaterina Maidji a, Mary E. Moreno a, Jose M. Rivera a, Ukina R. Sanford a, Barbara Sloan a,
Witold Cieplak b, Terri Wrin c, Po-Ying Chan-Hui b
a Division of Experimental Medicine, Department of Medicine, San Francisco General Hospital, University of California, Box 1234, San Francisco, San
Francisco, CA 94143, USA
b Theraclone Sciences, Inc., Seattle, WA 98104, USA
c Monogram Biosciences, South San Francisco, CA 94080, USA
a r t i c l e i n f o
Available online 25 June 2014
Keywords:
HIV pathogenesis
HIV infection
Humanized mouse
Neutralizing antibody
Passive immunization
a b s t r a c t
Highly potent broadly neutralizing human monoclonal antibodies hold promise for HIV prophylaxis and
treatment. We used the SCID-hu Thy/Liv and BLT humanized mouse models to study the efﬁcacy of these
antibodies, primarily PG16, against HIV-1 clades A, B, and C. PG16 targets a conserved epitope in the V1/
V2 region of gp120 common to 70–80% of HIV-1 isolates from multiple clades and has extremely potent
in vitro activity against HIVJR-CSF. PG16 was highly efﬁcacious in SCID-hu mice as a single intraperitoneal
administration the day before inoculation of R5-tropic HIV directly into their Thy/Liv implants and
demonstrated even greater efﬁcacy if PG16 administration was continued after Thy/Liv implant HIV
inoculation. However, PG16 as monotherapy had no activity in humanized mice with established
R5-tropic HIV infection. These results provide evidence of tissue penetration of the antibodies, which
could aid in their ability to prevent infection if virus crosses the mucosal barrier.
& 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Introduction
Human monoclonal antibodies that potently neutralize a broad
range of HIV isolates hold promise for the prevention of HIV
infection. The anti-gp120 broadly neutralizing monoclonal anti-
bodies 2G12 and b12 and anti-gp41 antibodies 4E10 and 2F5 block
diverse HIV variants because they target conserved, functionally
important Env epitopes (Muster et al., 1994; Roben et al., 1994;
Sagar et al., 2012; Stiegler et al., 2001; Trkola et al., 1996).
Importantly, passive transfer of these antibodies can protect
against intravenous (Mascola et al., 1999) and mucosal (Burton
et al., 2011; Hessell et al., 2009a, 2009b, 2010; Mascola et al., 2000;
Parren et al., 2001) challenge in macaque models of simian/HIV
(SHIV) infection. In recent years, several extraordinarily potent
neutralizing antibodies with activity against a wide range of HIV
clades have been discovered, including the somatically related
antibodies PG9 and PG16 (Davenport et al., 2011; Pancera et al.,
2010; Walker et al., 2009); VRC01 and VRC07 (Wu et al., 2010;
Zhou et al., 2010); CH01-CH04 (Bonsignori et al., 2011); and
3BNC117, NIH45-46, PGV04, and PGT121 and PGT128 (Diskin
et al., 2013, 2011; Falkowska et al., 2012; Scheid et al., 2011;
Walker et al., 2011; Wu et al., 2011). Sterilizing protection against
vaginal mucosal SHIV challenge has been achieved in macaques
with PGT121 (IC50 of 0.005 mg/ml against SHIVSF162P3) by passive
intravenous transfer of as little as 0.2 mg/kg, corresponding to a
“single-digit” serum concentration of 1.8 mg/ml at the time of virus
challenge (Moldt et al., 2012).
Encouraged by the highly potent neutralizing activity of PG16
against HIVJR-CSF in vitro (IC50 of 0.001 mg/ml), we sought to
determine whether PG16 would be effective as a prophylactic
modality against HIV challenge in humanized SCID-hu Thy/Liv
mice. PG16 targets the V1/V2 loop region at residues 160 and 162,
corresponding to a potential N-linked glycosylation site that may
form the PG16 epitope (McLellan et al., 2011; Pejchal et al., 2010;
Walker et al., 2009). The crystal structure of the antigen-binding
fragment (Fab) of PG16 revealed that the antibody is sulfated
and has a unique complementarity determining region (CDR) H3
subdomain structure with a stable stalk mediating extensive H3
protrusion from the combining site and two interconnected loops
(Pejchal et al., 2010).
The SCID-hu Thy/Liv mouse model of HIV infection is a useful
platform for the preclinical evaluation of antiviral efﬁcacy in vivo.
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The human thymus implant in these mice supports long-term
differentiation of human T cells, and the model has been standar-
dized and validated with four classes of licensed antiretrovirals for
the evaluation of antiviral drugs against HIV (Rabin et al., 1996;
Stoddart et al., 2007). One important advantage of SCID-hu Thy/Liv
mice for studies of HIV prophylaxis is their high (essentially 100%)
susceptibility to HIV infection after injection of the virus directly
into the thymus/liver implant. In previously reported humanized
mouse studies, b12 antibody completely protected hu-PBL-SCID
mice from intraperitoneal (i.p.) challenge with HIVJR-CSF but
only when administered at very high dosage levels (50 mg/kg)
(Gauduin et al., 1997). We hypothesized that PG16 would protect
against HIVJR-CSF infection at much lower dosage levels because it
is 4200 times more potent than b12 (IC50 of 0.001 versus
0.210 mg/ml) (Walker et al., 2009), and higher in vitro neutraliza-
tion potency of PGT-121 against SHIVSF162P3 has been shown to
translate into enhanced protection against virus challenge in
macaques (Moldt et al., 2012). In addition to HIVJR-CSF, we assessed
the prophylactic activity of PG16 against four other clade B and
non-clade B viruses in SCID-hu Thy/Liv mice and also explored the
potential for PG16 in treating established HIVJR-CSF infection.
Results
PG16 half-life in SCID-hu Thy/Liv mice
To determine the frequency of PG16 administration, we deter-
mined the half-life (t1/2) of PG16 in a separate pharmacokinetics
study performed in uninfected SCID-hu Thy/Liv mice. Mice were
treated with various doses of PG16 (5, 50, and 500 mg per mouse)
by i.p. injection, and the level of human IgG was measured by
ELISA in mouse serum collected 1, 3, and 6 days after treatment
(Fig. 1A). When administered at the highest dose (500 μg), PG16
exhibited an initial rapid decline during the ﬁrst 3 days, which
could be the result of a combination of IgG concentration-
dependent catabolism and distribution to extravascular spaces
(Lobo et al., 2004). Consistent with this explanation, the more
gradual decline from days 3 to 6 was similar for the 500-mg and
50-mg doses. The PG16 t1/2 was 3.7 days for the 500-mg dose and
4.2 days for the 50-mg dose (Fig. 1B). Importantly, the day after
PG16 administration (corresponding to the time of HIV challenge
in the protection studies), the mean level of human IgG in mouse
circulation was 78 μg/ml, 14 μg/ml, and o1.5 μg/ml for 500 mg,
50 mg and 5 mg PG16, respectively (Fig. 1A).
Untreated SCID-hu Thy/Liv mice (but not unengrafted CB17-scid
mice) had low levels (mean of 0.6 mg/ml) of human IgG in their
serum, likely resulting from the presence of small numbers of
human B cells (0.2–2.5% of implant cells) in the implants of these
mice (Namikawa, et al., 1990; Dittmer et al., 1999). On the day after
treatment with 5 mg PG16, the mean human IgG concentration was
1.5 mg/ml, a portion of which (0.3–1.1 mg/ml) was nonspeciﬁc
human IgG (Fig. 1C). Determination of the t1/2 for the 5 mg PG16
dose was therefore not possible because the pan-human IgG ELISA
cannot discriminate PG16 from endogenously produced human
IgG. Taking into account the results of the pharmacokinetics
experiments, we elected to give the antibody i.p. to the mice three
times per week (i.e., every other day) for studies involving
repeated administration of PG16.
Selection of HIV for SCID-hu Thy/Liv mouse protection studies
Because protection in vivo is generally highly correlated with
neutralization in vitro (Burton et al., 2011; Moldt et al., 2012),
before initiating our studies we evaluated PG16 in both pseudo-
virus and PBMC neutralization assays against several HIV isolates
that have been previously characterized in SCID-hu Thy/Liv mice
(Stoddart, et. al., 2007 and unpublished observations). The data
shown in Table 1 conﬁrm the extreme sensitivity of HIVJR-CSF and
lower susceptibility of HIVNL4-3 to PG16 (Walker et al., 2009). Of
the other six HIV clade B isolates in our SCID-hu Thy/Liv panel,
HIVJD was the most sensitive to PG16 neutralization with an IC50 of
0.008 mg/ml in the pseudovirus assay and 0.1 mg/ml with PBMC.
The PG16 resistance exhibited by four of these six clade B HIV
isolates in our SCID-hu panel (HIVPD, HIVEW, HIVEF, and HIVGV)
was unexpected given the reported broadly neutralizing activity
(80% of 162 pseudoviruses with IC50o50 μg/ml) of this anti-
body. We found that both HIVPD and HIVEW have the N160K
mutation in gp120 (data not shown), which explains the PG16
resistance of these primary isolates. However, no known PG16-
resistance mutations in the C1 through C2 regions of gp120 were
identiﬁed for the other two PG16-resistant isolates (HIVEF and
HIVGV). We also tested two non-clade B HIV isolates with the
greatest reported sensitivity to PG16 neutralization in Walker et al.
(2009) pseudovirus assay, clade A HIV92/RW/008 (IC50 0.002 mg/ml)
Fig. 1. PG16 serum half-life after a single administration of 5, 50, or 500 mg in SCID-hu Thy/Liv mice. (A) Mice were treated with PG16 by i.p. injection, and the level of human
IgG was measured by pan-human IgG ELISA in mouse serum collected 1, 3, and 6 days after treatment. (B) PG16 mean t1/2 was 3.7 days for the 500-mg dose and 4.2 days for
the 50-mg dose. (C) Untreated SCID-hu Thy/Liv mice (control) had low levels (mean of 0.6 mg/ml) of human IgG in their serum, so the t1/2 for the 5-mg PG16 dose could not be
accurately determined. On the day after treatment with 5 mg PG16, the mean human IgG concentration was 1.5 mg/ml, a portion of which (0.3–1.1 mg/ml) was nonspeciﬁc
human IgG, as demonstrated by the low levels in serum from untreated control SCID-hu Thy/Liv mice.
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and clade C HIV98/IN/022 (IC50 0.003 mg/ml). Except for HIVNL4-3, the
IC50 values for all viruses were substantially higher in PBMC than
in the pseudovirus assay. The two assays have previously been
reported to differ in assay sensitivity attributable to greater
envelope spike density and stability of pseudoviruses compared
to primary isolates, thus accounting for a higher sensitivity to
neutralization by pseudoviruses (Fenyo et al., 2009; Heyndrickx
et al., 2012).
Rationale and study design for in vivo protection studies
The ﬁrst set of experiments was performed in mice inoculated
with HIVJR-CSF, a molecular clone reported by Walker et al. (2009)
to be highly sensitive (IC50: 0.001 mg/ml) to PG16 neutralization
in vitro. The second set was performed with HIVJD, a dual/mixed
primary isolate in our SCID-hu mouse panel that was also highly
sensitive to PG16 in vitro, and a third set with HIVNL4-3, which was
less sensitive to PG16 with a plateau in dose response at o100%
neutralization. The fourth set of experiments was performed with
clade A and clade C isolates, and a ﬁnal set was carried out in mice
with established HIVJR-CSF infection to assess the potential of PG16
for HIV therapy. In each study, a range of PG16 dosage levels was
used to establish a dose–response effect. The dosage range was
very large (0.05–500 mg) across the studies for two main reasons: 1)
very high doses were used in an attempt to produce sterilizing
protection in the implants (which could rarely be achieved at
500 mg), and 2) very low doses were necessary to establish a no-
effect level in the mice for this extremely potent antibody. We
included in each study a positive control group treated with an
antiretroviral regimen (either 3TC or Truvada) known to have
reproducible efﬁcacy in the model.
Highly potent protection by PG16 against challenge with HIVJR-CSF
For studies with HIVJR-CSF, implants from SCID-hu Thy/Liv
mice were collected 42 days after inoculation, a time point when
HIVJR-CSF replication typically peaks in the implants, and assayed
for cell count, HIV RNA, and p24. In the ﬁrst study, mice were
injected i.p. with varying doses of PG16 starting the day before
inoculation and repeating every other day until Thy/Liv implant
collection. Speciﬁcally, groups of 5 or 6 mice each were given a
wide range of PG16 doses from 1.5 to 150 mg and challenged with
1000 50% tissue culture infectious doses (TCID50) of HIVJR-CSF by
direct injection of 50 ml virus into the implants of anesthetized
mice. In mice treated with as little as 1.5 mg (0.05 mg/kg) PG16, we
observed a 630-fold reduction in HIV RNA (from a mean of 104.7
HIV RNA copies per 106 cells in untreated mice to 101.9 copies in
PG16-treated mice) (Fig. 2A, Supplementary Table 1). In fact, three
of the ﬁve mice treated with 1.5 mg had no detectable viral RNA 42
days after inoculation, and all but one PG16-treated mouse (in the
5 mg group) had no detectable p24 (o5 pg per 106 cells) in their
implants. Mice in the positive antiviral control group treated twice
daily with 3TC (30 mg/kg/day) by i.p. injection had similarly large
reductions in viral RNA (from a mean of 104.7 to 101.8 copies per
106 cells) relative to untreated mice.
In the second study, we treated groups of 6 mice each with a
single prophylactic administration of 0.05, 0.5, or 5 mg PG16 or a
single administration of oral Truvada (200 mg/kg tenofovir dis-
oproxil fumarate [TDF] and 130 mg/kg emtricitabine [FTC] or
2000 mg/kg TDF and 1300 mg/kg FTC the day before HIVJR-CSF
challenge (Fig. 2B, Supplementary Table 2). In a previous report,
we showed that a single administration of Truvada the day before
inoculation had minimally protective activity against HIVNL4-3
challenge in the mice (Stoddart et al., 2012), unlike the much
more potent activity we reported for multiple licensed antiretro-
viral drugs when administered continually once or twice a day
until implant collection (Stoddart et al., 2007). We found that 5 mg
(0.18 mg/kg) PG16 reduced HIV RNA at 42 days by 79-fold (from a
mean of 105.0 to 103.1 copies per 106 cells) with no statistically
signiﬁcant reductions at the lower doses (Fig. 2B, Supplementary
Table 2). Despite the high dose, a single prophylactic administra-
tion of Truvada resulted in reductions in HIV RNA that were small
(from 105.0 to 104.6 copies per 106 cells) but statistically signiﬁcant
at the lower dose and not statistically signiﬁcant (because of
higher sample variance) at the higher dose 42 days after inocula-
tion (Fig. 2B). In the third study, we treated mice with a single
Table 1
HIV neutralization by P16 and PG9 in a pseudovirus reporter gene assay and with PBMC.
Virus Coreceptor usage Antibody Pseudovirus (luciferase) assay PBMC assay
IC50 (mg/ml) IC90 (mg/ml) IC50 (mg/ml) IC90 (mg/ml)
HIVJR-CSF R5 PG16 0.001 0.012 0.049 0.249
PG9 0.003 0.025 NDc ND
HIVJD R5X4 PG16 0.008 0.490 0.105 2.3
PG9 0.074 2.3 ND ND
HIVPD (N160K) X4 PG16 450 450 2.3 410
PG9 450 450 ND ND
HIVEW (N160K) X4 PG16 450 450 410 410
PG9 450 450 ND ND
HIVEF X4 PG16 450 450 410 410
PG9 450 450 ND ND
HIVJW R5 PG16 0.12 450 410 410
PG9 11 450 ND ND
HIVGV X4 PG16 450 450 410 410
PG9 450 450 ND ND
HIVNL4-3 X4 PG16 0.23 450 0.093 0.714
PG9 8.9 450 ND ND
HIV92/RW/008 (clade A) R5 PG16 0.002a NRb 0.046 0.520
PG9 0.01a NR ND ND
HIV98/IN/022 (clade C)a R5 PG16 0.003a NR 0.071 0.443
PG9 0.006a NR ND ND
IC50 and IC90 values represent the average of two separate assays for both pseudovirus and PBMC assays.
a Data from Walker et al. (2009). Number of replicates not speciﬁed.
b Not reported.
c Not determined.
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administration of 5 mg PG16 at 1, 7, and 14 days before HIVJR-CSF
inoculation and observed statistically signiﬁcant reductions in HIV
RNA for all three prophylactic time points (Fig. 2C, Supplementary
Table 3).
Potent protection by PG16 against challenge with HIVJD
Similar to the studies described above in SCID-hu Thy/Liv mice
inoculated with HIVJR-CSF, we found that PG16 also had potent
activity in mice inoculated with HIVJD. Mice were injected i.p. with
varying doses of PG16 starting one day before HIVJD injection and
repeating three times per week until peak virus replication and
implant collection 14 days after inoculation for cell count, HIV
RNA, and p24. We observed a 1600-fold reduction in HIV RNA in
mice given 500 mg PG16, a 2000-fold reduction in mice given
150 mg PG16, and a 630-fold reduction in those given 50 mg PG16
relative to untreated mice (Fig. 3A, Supplementary Table 4).
A human IgG1 isotype control antibody had no activity at the
highest dose of 500 mg given three times per week. In this same
study (Fig. 3A), we compared the activity of PG9, a somatically
related antibody, and PG16 at the 500-mg dose level and found
somewhat less protective activity for PG9 (320-fold reduction in
HIV RNA) compared to PG16 (1600-fold reduction). This difference
was also reﬂected in the lack of detectable p24 in PG16-treated
mice while 2 of 7 PG9-treated mice had 38 and 42 pg p24 per 106
implant cells, respectively (Supplementary Table 4). The greater
protective activity of PG16 compared to PG9 against HIVJD chal-
lenge is also consistent with the 9-fold lower pseudovirus neutra-
lization IC50 for PG16 (0.008 mg/ml) compared to PG9 (0.074 mg/ml)
(Table 1).
We performed two additional studies with progressively lower
doses to determine a minimally protective dose for PG16 against
HIVJD challenge. In the ﬁrst study, administration of as little as
1.5 mg PG16 three times per week for 14 days beginning the day
before virus inoculation resulted in a 1600-fold reduction in HIV
RNA (from a mean of 105.9 to 102.7 copies per 106 cells) and
reduced HIV p24 to undetectable levels in 5 of 6 mice (Fig. 3B,
Supplementary Table 5). In the subsequent study, the amount of
antibody was further reduced to determine the dose at which
PG16 had no measurable effect on HIV replication (Fig. 3C,
Supplementary Table 6). Here we determined the no-effect level
of PG16 to be 0.15 mg three times per week (Fig. 3C). When
administered as a single prophylactic dose of 5 mg, PG16 was
highly protective against HIVJD challenge with a 1600-fold reduc-
tion in HIV RNA (from a mean of 104.9 to 101.7 copies per 106 cells)
(Fig. 3C), which was substantially more effective than the 79-fold
reduction observed for HIVJR-CSF (Fig. 2B).
Protection by PG16 against challenge with HIVNL4-3
We next evaluated the prophylactic efﬁcacy of PG16 against
HIVNL4-3, which is less susceptible to PG16 neutralization in vitro
(Table 1). SCID-hu Thy/Liv mice were injected i.p. with 50, 150, or
500 mg PG16 starting one day before virus inoculation and repeating
three times per week until peak virus replication and implant
collection on day 21. In contrast to our ﬁndings with HIVJR-CSF and
HIVJD, high-dose (500 mg) PG16 had very low (2-fold reduction in HIV
RNA) protective activity against HIVNL4-3 (Fig. 4A, Supplementary
Table 7), consistent with the less potent neutralization of HIVNL4-3 by
PG16 observed in vitro (Table 1). In a separate study, treatment of the
mice with PG9 showed somewhat higher protective activity (25-fold
reduction in HIV RNA for 50 and 150 mg PG16) against HIVNL4-3
challenge (Fig. 4B, Supplementary Table 8).
Protective effects of a single administration of PG16 against challenge
with clade A HIV92/RW/008
The non-clade B HIV isolates reported by Walker et al. to have
the greatest sensitivity to PG16 neutralization, clade A HIV92/RW/008
and clade C HIV98/IN/022, were also evaluated in SCID-hu Thy/Liv
mice. There were statistically signiﬁcant reductions (8–16-fold) in
HIV RNA 42 days after inoculation in mice treated with a single
prophylactic administration of 5, 15, and 50 mg PG16 the day before
HIV92/RW/008 inoculation, but no protective effect was detected for
1.5 mg (Fig. 5A, Supplementary Table 9). Similarly to what we
observed for HIVJR-CSF (Fig. 2A), there was no statistically signiﬁ-
cant protective effect of a very high single oral administration of
Truvada given the day before HIV92/RW/008 inoculation. In contrast
to the moderate protective effects observed for HIV92/RW/008, no
signiﬁcant protective effect was observed after PG16 treatment of
H
IV
 R
N
A
 C
op
ie
s/
10
6  
C
el
ls
Untreated
1.5 5 15 50 150
PG16
******** ** **
0.05 0.18 0.53 1.8 5.3
µg
mg/kg
3TC
106
101
105
104
103
102
H
IV
 R
N
A
 C
op
ie
s/
10
6  
C
el
ls
Untreated
0.05 0.5 5
PG16
(once)
** *
0.002 0.02 0.2
µg
mg/kg
106
101
105
104
103
102
Truvada
(once)
200/130  2000/1300
mg/kg
H
IV
 R
N
A
 C
op
ie
s/
10
6  
C
el
ls
Untreated
PG16 (5 µg once)
***
–14 –7 –1
Days
**
106
101
105
104
103
102
-10 0 10 20 30 40
Inoculation
PG16
Implant
collection
or         or
Days after HIV
JR-CSF
inoculation
0 10 20 30 40
Days after  HIV
JR-CSF
inoculation
Inoculation
PG16
Implant
collection
0 10 20 30 40
Inoculation
PG16
Truvada
Implant
collection
Days after HIV
JR-CSF
inoculation
Fig. 2. PG16 protected SCID-hu Thy/Liv mice from infection with HIVJR-CSF in three independent challenge studies. (A) HIV RNAwas reduced to o102.0 copies per 106 implant
cells in mice treated i.p. with 1.5–150 mg PG16 (blue arrows) three times per week beginning the day before inoculation and continuing until implant collection at 42 days.
Similar reductions in HIV RNA were observed in mice treated i.p. with 30 mg/kg 3TC once daily beginning the day before inoculation until implant collection. (B) HIV RNA
was reduced to a mean of 103.0 copies per 106 cells in mice treated with a single administration of 5 mg PG16 the day before inoculation, which was a greater reduction than
observed in mice treated by oral gavage with a single administration of high doses of Truvada (200 mg/kg TDF plus 130 mg/kg FTC or 2000 mg/kg TDF plus 1300 mg/kg FTC).
(C) Statistically signiﬁcant reductions in HIV RNA occurred in mice treated with a single administration of 5 mg PG16 at 1, 7, and 14 days before inoculation. The columns
represent means, and the open circles represent individual mice. nnPo0.01 and nPo0.05 compared to untreated HIV-infected mice by the Mann–Whitney U test. The dotted
line indicates the HIV RNA detection limit. (101.5 copies per 106 implant cells).
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mice inoculated with clade C HIV98/IN/022 (Fig. 5B, Supplementary
Table 10) despite the high in vitro sensitivity of this strain to PG16.
Substantially reduced activity of PG16 when administered after
HIVJR-CSF challenge
We next evaluated the therapeutic activity of PG16 in HIVJR-CSF-
inoculated mice. Mice were treated with 5 mg PG16 three times per
week starting 1 day before or 8 or 15 days after HIVJR-CSF challenge
and with 50 mg PG16 three times per week starting 8, 15, or 22
days after HIVJR-CSF challenge. In comparison to starting PG16
treatment the day before inoculation, which showed the expected
protective effect with 5 mg PG16, delay of treatment initiation to
8 days after inoculation resulted in only 2.5–3-fold HIV-inhibitory
activity (from a mean of 105.3 HIV RNA copies per 106 cells in
untreated mice to 104.8-4.9 copies in all groups treated after
inoculation (Fig. 6A, Supplementary Table 11). In a separate study
where SCID-hu Thy/Liv mice with established HIVJR-CSF infection
were treated 17 weeks after inoculation with 500 mg PG16 admi-
nistered three times per week for 3 weeks, no protection was
observed (Fig. 6B, Supplementary Table 12).
It is difﬁcult to achieve signiﬁcant and sustained antiviral
activity in SCID-hu Thy/Liv mice with established HIV infection
even with high-dose combination therapy including a protease
inhibitor (Amado et al., 1999). Mindful of this potential limitation
with the SCID-hu Thy/Liv model, we also treated NOD-scid
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Fig. 4. PG16 and PG9 exhibited minimal protective activity in SCID-hu Thy/Liv mice challenged with HIVNL4-3. (A) Statistically signiﬁcant reductions in HIV RNA occurred in
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IL-2Rγ / (NSG) BLT mice (NSG-BLT) mice with established
HIV infection and stable viremia. In the NSG-BLT model, Thy/Liv
implantation is supplemented by the injection of CD34þ
hematopoietic stem/progenitor cells (HSPC) isolated from the
autologous fetal liver. The Thy/Liv implant allows for positive
and negative selection of human T cells to occur in autologous
human thymus tissue, while the injected HSPC populate the
mouse bone marrow to reconstitute and maintain human hema-
topoiesis. This approach leads to the most comprehensive recon-
stitution of the human immune system in a mouse model yet
reported, with high levels of multilineage human cell engraftment
and sustained HIV plasma viremia after parenteral and mucosal
HIV exposure.
We treated groups of 6–7 HIV-viremic NSG-BLT mice with a
very high dose of PG16 (1.5 mg) or PBS vehicle 6 and 12 weeks
after i.p. HIVJR-CSF inoculation and observed no reduction in plasma
HIV RNA after the ﬁrst administration and up to 7 days after the
second administration (Fig. 6C, Supplementary Table 13). Plasma
viral load increased dramatically in one mouse after the ﬁrst PG16
treatment, but this mouse had evidence of graft-versus host
disease necessitating euthanasia before the second PG16 treat-
ment. To determine whether viral escape from PG16 had occurred
in the mice, we sequenced gp120 RNA obtained from spleens
1 week after the second PG16 administration and observed a
mutation at residue 162 (T162N) in two of the six treated mice.
Outgrowth of T162N was also reported in the previous work in
Fig. 5. A single administration of PG16 protected SCID-hu Thy/Liv mice from challenge with clade A HIV92/RW/008 but not clade C HIV98/IN/022. (A) HIV RNA was reduced by
1 log10 in mice treated with a single administration of 5–50 mg PG16 the day before inoculation with HIV92/RW/008, unlike mice treated once by oral gavage with high-dose
Truvada (2000 mg/kg TDF plus 1300 mg/kg FTC), which had no reductions in viral RNA 42 days after inoculation. (B) No reductions in HIV RNAwere observed in mice treated
with a single administration of 1.5–50 mg PG16 the day before inoculation with HIV98/IN/022. The columns represent means, and the open circles represent individual mice.
nnPo0.01, nPo0.05 compared to untreated HIV-infected mice by the Mann–Whitney U test. The dotted line indicates the HIV RNA detection limit. (101.5 copies per 106
implant cells).
Fig. 6. PG16 had substantially reduced activity in SCID-hu Thy/Liv mice when treatment was initiated 8 days or more after HIVJR-CSF inoculation and had no signiﬁcant
activity in both SCID-hu Thy/Liv mice and NSG-BLT mice with established HIVJR-CSF infection. (A) HIV RNA was reduced by 1 log10 in SCID-hu Thy/Liv mice treated i.p. with
5 mg PG16 three times per week beginning the day before inoculation and continuing until implant collection at 42 days. Smaller reductions in HIV RNAwere observed when
treatment was delayed until 8 or more days after inoculation. The columns represent means, and the open circles represent individual mice. nnPo0.01 and nPo0.05
compared to untreated HIV-infected mice by the Mann–Whitney U test. (B) No reduction in HIV RNA in SCID-hu Thy/Liv mice treated i.p. with high-dose (500 mg) PG16 or
PBS three times per week for 3 weeks beginning 17 weeks after HIVJR-CSF inoculation. The dotted line indicates the HIV RNA detection limit. (101.5 copies per 106 implant
cells). (C) Viremic NSG-BLT mice were treated with 1.5 mg PG16 at 6 and 12 weeks after intravaginal HIVJR-CSF inoculation. Each line represents an individual mouse, and
sequence analysis of viral RNA from the spleens of PG16-treated mouse #5 and #29 (Supplementary Table 13) revealed Env mutation T162N (data not shown). Mouse #15
died and mouse #21 was euthanized with clinical signs consistent with graft-versus-host disease.
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PG16-treated humanized NRG mice along with other substitutions
at positions T162 and N160, and these mutants were found to be
highly resistant to PG16 neutralization in vitro (Klein et al., 2012).
It is unlikely, however, that the lack of protective activity we
observed was the result of viral escape because we detected PG16-
resistance mutations in only 2 of 6 mice with established HIVJR-CSF
infection.
Discussion
The broadly HIV-neutralizing antibodies PG9 and PG16 were
isolated from an African clade A-infected individual, who ranked in
the top 5% of 1800 HIV-infected donors screened for potent anti-
HIV serum neutralizing activity in an international effort named
Protocol G (Walker et al., 2009). From a panel of 162 HIV isolates,
PG9 neutralized 127 and PG16 neutralized 119 of derived pseudo-
viruses with potencies 1 log10 greater than broadly neutralizing
antibodies 2G12, b12, 2F5, and 4E10 (Doores and Burton, 2010) and
comparable to that of VRC01 (Wu et al., 2010).
In the present study, we evaluated both the prophylactic and
therapeutic activities of PG16 against HIV challenge in humanized
mice. We used ﬁve different challenge isolates that were sensitive to
PG16 neutralization in vitro (Table 1), including a clade A (HIV92/
RW008) and a clade C (HIV98/IN/022) isolate (Table 1). The IC50 values for
PG16 ranged from 0.001 mg/ml for HIVJR-CSF to 0.23 mg/ml for HIVNL4-3
in the in vitro pseudovirus assay. It is notable that four of our primary
isolates (HIVPD, HIVEW, HIVEF, and HIVGV) were resistant to PG9 and
PG16 (IC50 450 mg/ml) and that they were all X4 tropic whereas the
sensitive viruses were either R5 (HIVJR-CSF, HIVJW, HIV92/RW008, and
HIV98/IN/022) or R5X4 (HIVJD). This unusual pattern of neutralization
sensitivity may be limited to our small sample size.
In our prophylaxis studies, we treated SCID-hu Thy/Liv mice
with either a single prophylactic administration the day before HIV
inoculation or repeated treatment three times per week beginning
the day before inoculation until implant collection 14–42 days
after inoculation, depending on peak virus replication for the
respective challenge virus (14 days for R5X4 HIVJD, 21 days for
X4 HIVNL4-3, and 42 days for R5 strains HIVJR-CSF, HIV92/RW008, and
HIV98/IN/022). We chose the intrathymic HIV exposure route
because injection of HIV directly into the human target tissue
provides a more stringent assessment of the efﬁcacy of the test
agent under various study designs compared to the mucosal or
intravenous routes, for which exposure of the virus to target
organs is less direct.
In an initial dose-ranging study with the most PG16-sensitive
isolate, HIVJR-CSF, we observed a 630-fold reduction in HIV RNA
in mice treated with the lowest PG16 dose evaluated, 1.5 mg
(0.05 mg/kg), starting the day before virus inoculation and repeat-
ing three times per week for 42 days. In a second study, we gave
the mice a single administration of PG16 the day before HIVJR-CSF
challenge and found that 5 mg (0.2 mg/kg) reduced HIV RNA by 79-
fold. The latter results are comparable to those reported by
Gauduin et al. (1997) where 80% (actual number not speciﬁed)
of hu-PBL-SCID mice were protected by a single administration of
1 mg/kg b12 antibody 1 h before i.p. inoculation with HIVLAI. In our
SCID-hu Thy/Liv mouse model, mice treated with 5 mg PG16 had an
antibody serum concentration of o1.5 mg/ml the day after treat-
ment, indicating a protective serum concentration for PG16 that is
in the single-digit mg/ml range, similar to that recently reported for
PGT121 in macaques protected from mucosal SHIV challenge
(Moldt et al., 2012). The t1/2 of 3.7 days we obtained corresponds
well to the 2.5 days reported for a 500-mg dose of PG16 by Klein
et al. (2012) in humanized NOD Rag1 /IL2Rγ / (NRG) mice
reconstituted with human fetal liver-derived CD34þ cells at birth.
Compared to a single administration of 0.2 mg/kg (5 mg) PG16, a
single very large dose of Truvada (2000 mg/kg TDF and 1300 mg/
kg FTC) resulted in only relatively small reductions in HIV RNA in
HIVJR-CSF-challenged mice (Fig. 2B). We previously reported simi-
larly small reductions in HIV RNA after a single preexposure
administration of Truvada in SCID-hu Thy/Liv mice inoculated
with HIVNL4-3 (Stoddart et al., 2012). The potent activity of a single
administration of PG16 observed in the present study is reminis-
cent of the sustained activity obtained for an albumin-conjugated
C34 peptide fusion inhibitor with prolonged plasma half-life
(20 h rats) in that previous report (Stoddart et al., 2012). More-
over, we showed that a single treatment with PG16 had sustained,
although lower, activity when HIVJR-CSF challenge was delayed by
up to 7 or 14 days.
PG16 was also highly protective against HIVJD challenge, with a
1600-fold reduction in HIV RNA and lack of detectable p24 in 5 of
6 mice treated with 1.5 mg three times per week for 14 days and a
1300-fold reduction in HIV RNA after a single prophylactic admin-
istration of 5 mg. In contrast, the somatically related PG9 antibody
was somewhat less protective than PG16 at the 500-mg dose
level. The greater protective activity of PG16 compared to PG9
against HIVJD challenge is consistent with the 9-fold lower
pseudovirus neutralization IC50 for PG16 (0.008 mg/ml) compared
to PG9 (0.074 mg/ml).
In contrast to our ﬁndings with HIVJR-CSF and HIVJD, high-dose
(500 mg) PG16 had minimal protective activity against HIVNL4-3
when administered three times per week, which is consistent with
the less potent neutralization of HIVNL4-3 by PG16 observed
in vitro. It should be noted that, unlike for other viruses, the PG9
and PG16 pseudovirus neutralization curves for HIVNL4-3 plateaued
at o100% neutralization (Walker et al., 2009), and this was
conﬁrmed in our study. The PG16 dose–response curves for
HIVNL4-3 in the PBMC assay did not plateau with a relatively low
IC90 value of 0.7 mg/ml (Table 1). This incomplete in vitro neutra-
lization appears to be reﬂected in the plateaued dose responses we
obtained for PG9 and PG16 in HIVNL4-3-challenged mice.
Contrary to predictions from in vitro neutralization potency, a
single prophylactic administration of up to 50 mg PG16 had 1 log10
lower protective activity against challenge with clade A HIV92/RW/008
than against HIVJR-CSF. No detectable activity against clade C HIV98/
IN/022 was observed. Similar to HIVJR-CSF, both of these isolates have
the greatest in vitro sensitivity to PG16 neutralization (IC50 0.002–
0.003 mg/ml), so the difference in in vivo protection against these
non-clade B isolates was unexpected. While a higher dosage of
antibody or repeated treatment during the infection period may
have resulted in more potent protection from HIV92/RW/008 and
HIV98/IN/022 challenge, it remains unclear whether the lack of
greater protection with a single administration is associated with
differences in their infection behavior in SCID-hu Thy/Liv mice
despite the fact that they have the same tropism.
We compared the prophylactic and therapeutic activities of
PG16 in a series of experiments. First, we treated SCID-hu Thy/Liv
mice with 5 mg PG16 three times per week starting 1 day before or
8 or 15 days after HIVJR-CSF challenge and with 50 mg PG16 three
times per week starting 8, 15, or 22 days after HIVJR-CSF challenge.
Although repeated dosing of 5 mg PG16 starting the day before
inoculation had the expected protective effect, delay of treatment
initiation after inoculation resulted in little protective activity.
Since it remained possible that a higher repeated dosage of PG16
would lead to reductions in HIV RNA in the implants, we further
evaluated the therapeutic activity of high-dose PG16 in established
HIV infection in two separate studies. In one study, a high repeat-
dose PG16 treatment of SCID-hu Thy/Liv mice at 500 mg (18 mg/kg)
for 3 weeks starting 17 weeks after HIVJR-CSF inoculation had no
effect on HIV RNA levels in the implants 3 weeks after treatment.
This limited efﬁcacy in established HIV infection is consistent with
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results reported previously for b12, 2G12, 2F5, or their combina-
tion using hu-PBL-SCID mice (Poignard et al., 1999).
In the second study using HIV-viremic NSG-BLT mice, a very
high dose of PG16 (1.5 mg or 54 mg/kg) at 6 and 12 weeks after i.p.
HIVJR-CSF challenge resulted in no reduction in plasma HIV RNA
measured 2 and 4 weeks after the ﬁrst treatment and 1 week after
the second treatment. In both of these models, the lack of
therapeutic efﬁcacy by PG16 might be the result of using antibody
monotherapy. This possibility is supported by the results from a
recent report where PG16 was evaluated in an established infec-
tion model in humanized NOD Rag1 /Il2rγnull (NRG) mice that
were reconstituted with human fetal liver-derived CD34þ cells at
birth (Klein et al., 2012). In that report, mice were given 500 mg
(20 mg/kg) PG16 once or twice a week after infection was
established by i.p. challenge with HIVYU-2, a clone of HIVNL4-3
carrying the envelope of YU-2, and only a transient reduction of
HIV RNA was detected before virus rebound. Moreover, unlike the
NRG mice, in which nearly all rebound virus contained escape
mutations at N160 or N162, we detected viral escape in the
rebound virus population after two administrations of 1.5 mg
(54 mg/kg) PG16 in only two of the six SCID-hu Thy/Liv mice.
Overall, the observed effect of PG16 treatment in these two models
of established JR-CSF infection was limited by the antibody
monotherapy regimen we used. Recently, a combination of PG16
with an anti-CD4 binding sites and an anti-V1/V2 loop antibody
administered at 1 mg each (40 mg/kg) twice a week rapidly
suppressed plasma viral RNA in NRG mice with established
HIVYU-2 infection and demonstrated the protective activity of
PG16 and its therapeutic potential in the context of combination
therapy (Horwitz et al., 2013).
The current study conﬁrms the usefulness of the SCID-hu Thy/
Liv mouse model for evaluation of in vivo preexposure prophylaxis
of human HIV-speciﬁc monoclonal antibodies and demonstrates
the utility of in vitro characterization of challenge viruses prior to
in vivo experimentation. The high (essentially 100%) HIV suscept-
ibility of SCID-hu Thy/Liv mice across many cohorts makes such
prophylaxis experiments feasible because it increases conﬁdence
that the observed protection is not the result of poor susceptibility
to infection.
A major advantage of the BLT mouse model is the establish-
ment of systemic HIV infection and plasma viremia after HIV
challenge by multiple routes; the model's major drawbacks are
variability between mice in HIV susceptibility (Long and Stoddart,
2012) and a high incidence (35% by 22 weeks) of GvHD (Greenblatt
et al., 2012; Covassin et al., 2013), which might have perturbed the
efﬁcacy of PG16 in the BLT mice. Indeed, we show in Fig. 6C a spike
in HIV viremia in a PG16-treated mouse experiencing signs of
GvHD and surmise that systemic immune activation driven by the
GvHD disease process may have led to greater HIV expression.
According to Greenblatt et al., GvHD in BLT mice is associated with
the inﬁltration of human CD4þ T cells into the skin and a shift
towards Th1 cytokine production. GvHD also induced a mixed
M1/M2 polarization phenotype in a dermal murine macrophage
population that is CD11bþ and MHC class IIþ . GVHD mice
displayed robust expression of human IFNγ and the proﬁbrotic
mediators human IL13 and human CCL2. The presence of xeno-
geneic GvHD in BLT mice presents both a major obstacle in the use
of humanized mice and an opportunity to conduct preclinical
studies on GvHD in a humanized model.
In summary, our results demonstrate the ability of PG16 to
penetrate and protect primary lymphoid tissues from HIV infec-
tion and that antibodies can work in central immune sites, not just
at the mucosal surface. This feature could add to the broadly
neutralizing monoclonal antibodies' ability to prevent infection if
HIV crosses the mucosal barrier. Overall, these ﬁndings suggest
that this antibody or similar agents with high potency and
sustained activity may hold promise as a single intervention
modality or in cocktail combinations (to prevent viral escape) for
targeting early infection events after HIV exposure. The potent
protective efﬁcacy we observed for a single preexposure adminis-
tration supports further preclinical and clinical evaluation of this
promising passive immunization strategy.
Materials and methods
Viruses
The following reagents were obtained through the NIH AIDS
Research and Reference Reagent Program, Division of AIDS, NIAID,
NIH: HIV molecular clones pYK-JRCSF (R5) from Dr. Irvin SY Chen
and Dr. Yoshio Koyanagi (Cann et al., 1990; Haltiner et al., 1985;
Koyanagi et al., 1987), pNL4-3 (X4) from Dr. Malcolm Martin
(Adachi et al., 1986), and HIV-1 92RW008 (clade A) and 98IN022
(clade C) (from The UNAIDS Network for HIV Isolation and
Characterization). Primary HIV isolates HIVJD (Kovalev et al.,
1999; Stoddart et al., 2007; Su et al., 1995), HIVEW (Kovalev et al.,
1999; Rabin et al., 1996; Su et al., 1995), HIVPD, HIVEF, HIVJW, and
HIVGV were obtained from Dr. J. M. McCune. Working stocks of the
molecular clones were prepared in HEK 293T cells by lipofecta-
mine 2000 transfection, and primary isolates were expanded in
phytohemagglutinin (PHA)-activated peripheral blood mononuc-
lear cells. Stock virus titers (50% tissue culture infectious doses;
TCID50) were determined in PHA-activated PBMC by 50% endpoint
dilution and assessment of supernatant p24 by ELISA after 7 days.
Antibodies and drugs
PG16 and PG9 were provided by Theraclone Sciences and were
puriﬁed chromatographically from cultures of CHO-S1 cells cotrans-
duced with PG16 or PG9 heavy and light chain genes (Bleck, 2012).
Lamivudine (3TC), tenofovir disoproxil fumarate (TDF), and emtricita-
bine (FTC) were kindly provided by the NIH AIDS Research and
Reference Reagent Program. PG16 in mouse serum was measured by
ELISA for human IgG (Bethyl Laboratories).
in vitro neutralization assays
Pseudoviruses were produced by cotransfection of HEK 293
cells with a subgenomic plasmid, pHIV-1lucΔu3, that incorporates
a ﬁreﬂy luciferase indicator gene and a second plasmid, pCXAS,
that expresses HIV-1 Env libraries or clones. Following transfec-
tion, pseudoviruses were harvested and used to infect U87 cell
lines expressing either CCR5 or CXCR4 (Richman et al., 2003).
PHA-activated PBMCs pooled from six donors were inoculated
with HIV-1 at an MOI of 0.001 for 2 h at 37 1C, and triplicate wells
of round-bottom 96-well plates containing 100,000 cells in 100 ml
were treated with 100 ml of serially diluted antibody or medium
alone and cultured for 7 days. Supernatants were collected and
assayed for p24 antigen at 1:800 dilution in HIV p24 antibody-
coated microplates (Perkin-Elmer) by quantitative ELISA using the
p24 standard supplied by the manufacturer. IC50 values were
determined by a 4-parameter ﬁt model (SOFTmax PRO 3.0,
Molecular Devices). At day 7, untreated virus control wells had
mean p24 concentrations of 5–20 ng/ml.
SCID-hu Thy/Liv mice
Male C.B-17 SCID (model #CB17SC-M, homozygous, C.B-Igh-1b/IcrTac-
Prkdcscid) mice were obtained at 6–8 weeks of age from Taconic and
coimplanted with 1-mm3 pieces of human fetal thymus and liver
under the kidney capsule to generate SCID-hu Thy/Liv mice as
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described previously (Rabin et al., 1996; Stoddart et al., 2007). Cohorts
of 50–60 mice each were generated from the tissues of one donor, and
implants were inoculated 18 weeks after implantation with 50 ml of
stock virus (1000 TCID50) or RPMI 1640 medium (mock infection) by
direct injection into the implants of anesthetized mice. Each experi-
ment was performed in a separate SCID-hu Thy/Liv mouse cohort,
and details for the twelve cohorts are shown in Supplementary
Tables 1–12. Of the 559 mice included in the studies, 20 (3.6%) mice
died during the course of the experiment, and 22 (3.9%) mice had
abnormal implants and were excluded from analysis.
Antibodies were administered i.p. to the mice (5–7 mice per
group) at the indicated dosages beginning, in most experiments,
the day before inoculation of the Thy/Liv implants. Thy/Liv
implants were collected from euthanized mice 14 days after
inoculation with HIVJD inoculation, 21 days after HIVNL4-3, and
42 days after HIVJR-CSF, HIV92RW008, and HIV98IN022 when virus
replication peaks in the implants with these isolates. Animal
protocols were approved by the UCSF Institutional Animal Care
and Use Committee.
NSG-BLT mice
One cohort of humanized NOD-scid IL-2Rγ / (NSG) BLT mice
(NSG-BLT) was used to study PG16 treatment of established HIV
infection. NSG-BLT mice were produced as described previously
(Lan et al., 2006; Long and Stoddart, 2012; Melkus et al., 2006) by
coimplanting human fetal liver and thymus under the kidney
capsule of NSG mice (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ; Jackson
Laboratories). Human CD34þ hematopoietic stem progenitor cells
were puriﬁed from fetal liver by magnetic bead selection and
cryopreserved until tail vein injection (815,000 cells per mouse)
3 weeks after Thy/Liv implantation and 30 h after conditioning
with 225 cGy gamma irradiation. Of the cells injected, 917 were
CD45þ , CD34þ , Lin-1neg, CD38neg, C-kitþ , CD90þ , and CD45RAneg
human hematopoietic stem cells (HSC) (Long and Stoddart, 2012).
NSG-BLT mice were inoculated intravaginally with HIVJR-CSF (8000
TCID50) 12 weeks after CD34þ cell injection.
Thy/Liv implant processing and assay
Single-cell suspensions were made by placing the implant into a
sterile nylon mesh bag, submerging the bag in phosphate-buffered
saline (PBS)/2% fetal bovine serum (FBS) in a 60-mm tissue culture
dish, and dispersing the tissue between the nylon layers with forceps,
as described previously (Rabin et al., 1996; Stoddart et al., 2007,
2000). The cells were counted with a Coulter counter to determine
total implant cellularity. For the bDNA assay, dry pellets of 5106
implant cells were frozen and stored at 801C. Cells were disrupted
with sterile disposable pestles and a cordless motor grinder (Kontes)
in 8 M guanidine HCl with 0.5% sodium N-lauroylsarcosine. The RNA
was extracted with 0.5 ml 100% ethanol and pelleted at 12,000g for
20 min at 4 1C. Supernatants were aspirated to remove DNA, and
RNA pellets were washed with 0.5 ml 70% ethanol, placed on dry ice,
and digested with reagents supplied by the manufacturer
(VERSANT™ HIV-1 RNA 3.0 Assay, Siemens Healthcare Diagnostics).
Implant HIV RNA is expressed as copies per 106 implant thymocytes,
and the log10 values were used for calculation of geometric means.
The limit of detection was 101.48 RNA copies per 106 cells, and this
lower-limit value was used for calculation of means for implants with
undetectable viral RNA. For p24 ELISA, pellets of 2.5106 cells were
resuspended in 400 ml of p24 lysing buffer (1% Triton X-100, 0.5%
sodium deoxycholate, 5 mM EDTA, 25 mM Tris Cl, 250 mM NaCl, and
1% aprotinin), rotated overnight at 4 1C, and stored at 201C. Thawed
samples were transferred into HIV p24 antibody-coated microplates
(PerkinElmer Life Sciences) for quantitative ELISA. A standard curve
was generated with the kit-supplied standards, and the results were
calculated as pg p24 per 106 cells. Implant cells were also stained
with antibodies to CD3, CD4, and CD8 for analysis of T-cell subsets by
multiparameter ﬂow cytometry (Supplementary material).
Statistical analysis
Results are expressed as the mean7SEM for each mouse
group. Nonparametric statistical analyses were performed by use
of the Mann–Whitney U test. Data for mice in each group were
compared to those for untreated infected mice, and P values
o0.05 were considered statistically signiﬁcant.
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